Moore Capital Management LP Acquires Shares of 116,204 Accolade, Inc. (NASDAQ:ACCD)

Moore Capital Management LP acquired a new stake in shares of Accolade, Inc. (NASDAQ:ACCD) in the 4th quarter, Holdings Channel.com reports. The fund acquired 116,204 shares of the company’s stock, valued at approximately $397,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nisa Investment Advisors LLC boosted its holdings in shares of Accolade by 15,113.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 55,680 shares of the company’s stock valued at $190,000 after purchasing an additional 55,314 shares during the last quarter. Barclays PLC boosted its holdings in shares of Accolade by 164.4% during the 3rd quarter. Barclays PLC now owns 139,901 shares of the company’s stock valued at $539,000 after purchasing an additional 86,981 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Accolade during the 4th quarter valued at about $120,000. Savant Capital LLC boosted its holdings in shares of Accolade by 182.1% during the 4th quarter. Savant Capital LLC now owns 52,794 shares of the company’s stock valued at $181,000 after purchasing an additional 34,082 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Accolade by 1.7% during the 4th quarter. Rhumbline Advisers now owns 115,136 shares of the company’s stock valued at $394,000 after purchasing an additional 1,967 shares during the last quarter. Institutional investors own 84.99% of the company’s stock.

Accolade Price Performance

Shares of NASDAQ ACCD opened at $7.02 on Wednesday. The firm’s 50-day moving average price is $7.01 and its 200-day moving average price is $5.71. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $575.59 million, a price-to-earnings ratio of -3.12 and a beta of 2.10. Accolade, Inc. has a 12-month low of $3.08 and a 12-month high of $8.05.

Analysts Set New Price Targets

Several research firms have commented on ACCD. Stephens reissued an “equal weight” rating and set a $7.03 price objective on shares of Accolade in a report on Wednesday, February 12th. Piper Sandler cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Thirteen research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.51.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.